Davis's Drug Guide
momelotinib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
moe-me-loe-ti-nib
Trade Name(s)
- Ojjaara
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Momelotinib." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580067/all/momelotinib.
Vallerand AHA, Sanoski CAC, . Momelotinib. Davis's Drug Guide. F.A. Davis Company; 2025. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580067/all/momelotinib. Accessed April 20, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Momelotinib. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580067/all/momelotinib
Vallerand AHA, Sanoski CAC, . Momelotinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 April 20]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580067/all/momelotinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - momelotinib
ID - 3580067
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580067/all/momelotinib
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
